Group I harbored activating mutations in FLT3, MLL fusions and are classified as AML M5; Group II was enriched for loss of function TP53 mutations and three of the four cell lines were CML and thus had BCR-ABL1 fusions; Group III was characterized by activating mutations in genes involved in growth factor signaling such as RAS or JAK2, whereas no clear pattern was detected for Group IV. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.